In a different study, a vaccine that used 19 peptides derived from 11 tumor-associated antigens, such as squamous cell carcinoma antigen (3SART3), leukocyte-specific protein tyrosine kinase (Lck), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and epidermal growth factor receptor (EGFR), was evaluated in triple-negative breast cancer patients. This evidence concerns the gene KLK3 and triple-negative breast carcinoma.